Search Results

Now showing 1 - 3 of 3

Some of the metrics are blocked by your
consent settings
Galectin-3 as a Biomarker of Disease Severity in Acute-on-Chronic Liver Failure
(2020)
Cervantes-Álvarez, Eduardo
;
Limón-de la Rosa, Nathaly
;
Vilatoba, Mario
;
Pérez-Monter, Carlos
;
Hurtado-Gómez, Sahara
*Purpose: A matter of great importance is the discovery of alternative diagnostic measures that can detect liver disease at an early stage, especially when at risk of developing acute on chronic liver failure (ACLF), to optimize outcome and survival. Galectin-3 (Gal-3) is a lectin that binds to β-galactosides and can be secreted to the systemic circulation, regulating inflammation and fibrosis. Due to its direct role in inflammation and fibrosis, levels of this lectin can reflect the progression of liver damage and the possible consequent multiorgan failure, which is a distinctive characteristic of ACLF. The purpose of this study is to determine if liver Gal-3 expression is a useful biomarker of disease progression. *Methods: Liver samples from cirrhotic patients with compensated, decompensated cirrhosis and ACLF were collected at the time of liver transplant. The liver from donors was used as controls. RNA was extracted and liver Gal-3 expression was analyzed by quantitative polymerase chain reaction (qPCR). The values obtained were correlated with clinical and biochemical parameters using Pearson’s and Spearman’s correlation coefficients. A comparison among 3 different groups was performed using the Kruskal-Wallis test with Dunn’s multiple comparisons test.
51 2
Some of the metrics are blocked by your
consent settings
Liver transplantation is beneficial regardless of cirrhosis stage or acute-on-chronic liver failure grade: A single-center experience
(2022)
Cervantes-Álvarez, Eduardo
;
Vilatoba, Mario
;
Limón-de la Rosa, Nathaly
;
Méndez-Guerrero, Osvely
;
Kershenobich, David
Background: Liver transplantation for the most critically ill remains controversial; however, it is currently the only curative treatment option. Aim: To assess immediate posttransplant outcomes and compare the short (1 year) and long-term (6 years) posttransplant survival among cirrhotic patients stratified by disease severity. Methods: We included cirrhotic patients undergoing liver transplantation between 2015 and 2019 and categorized them into compensated cirrhosis (CC), decompensated cirrhosis (DC), and acute-on-chronic liver failure (ACLF). ACLF was further divided into severity grades. Our primary outcomes of interest were total days of intensive care unit (ICU) and hospital stay, development of complications and posttransplant survival at 1 and 6 years. ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Scopus© Citations 5 30 2
Some of the metrics are blocked by your
consent settings
Galectin‐3 is overexpressed in advanced cirrhosis and predicts post‐liver transplant infectious complications
(2022)
Cervantes‐Alvarez, Eduardo
;
Limón-de la Rosa, Nathaly
;
Vilatoba, Mario
;
Pérez Nicomedes, Carlos
;
Hurtado‐Gomez, Sahara
Background & aims: Patients with advanced cirrhosis often have immune dysfunction and are more susceptible to infections. Galectin-3 is a β-galactoside-binding lectin implicated in inflammation, immune regulation and liver fibrosis. We aim to investigate galectin-3 expression in advanced cirrhosis and its ability to predict post-transplant infectious complications. Methods: We collected sera and liver samples from 129 cirrhotic patients at the time of liver transplantation and from an external cohort of 37 patients with alcoholic liver disease including alcoholic hepatitis (AH) at the time of diagnosis. Galectin-3 was assessed by ELISA, real-time PCR, immunohistochemistry and RNA-seq. Receiver operating characteristic curves and Cox proportional-hazards regression analysis were performed to assess the predictive power of galectin-3 for disease severity and post-transplant infections.
Scopus© Citations 14 23 1

CRIS

Browse

Filters

Settings

Sort By

Results per page

Search Results